Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review. (Q39140474)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28211611%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

title

Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28211611%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

0 references

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28211611%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

author name string

Anders Albèr

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28211611%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Andreas Brønden

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28211611%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

publication date

17 March 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28211611%20AND%20SRC:MED&resulttype=core&format=json

Diabetes, Obesity and Metabolism

3 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28211611%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28211611%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

915-925

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28211611%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28211611%20AND%20SRC:MED&resulttype=core&format=json

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

3 April 2020

cites work

1 reference

Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study

21 January 2018

1 reference

Hypoglycemia in diabetes.

21 January 2018

1 reference

Temporal patterns in overweight and obesity in Type 1 diabetes

21 January 2018

1 reference

Prevalence and comorbidities of double diabetes

21 January 2018

1 reference

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

21 January 2018

1 reference

Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients

21 January 2018

1 reference

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.

21 January 2018

1 reference

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

21 January 2018

1 reference

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans

21 January 2018

1 reference

GLP-1 agonists in type 1 diabetes

21 January 2018

1 reference

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

21 January 2018

1 reference

Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists

21 January 2018

1 reference

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis

21 January 2018

1 reference

Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes

21 January 2018

1 reference

The role of adjunctive exenatide therapy in pediatric type 1 diabetes

21 January 2018

1 reference

Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges

21 January 2018

1 reference

Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm

21 January 2018

1 reference

Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes

21 January 2018

1 reference

Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes.

21 January 2018

1 reference

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.

21 January 2018

1 reference

Once-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy.

21 January 2018

1 reference

Type 1 diabetes treatment beyond insulin: role of GLP-1 analogs

21 January 2018

1 reference

Liraglutide as additional treatment to insulin in obese patients with type 1 diabetes mellitus.

21 January 2018

1 reference

Liraglutide as additional treatment for type 1 diabetes.

21 January 2018

1 reference

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function

21 January 2018

1 reference

GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach

21 January 2018

1 reference

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.

21 January 2018

1 reference

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.

21 January 2018

1 reference

Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus

21 January 2018

1 reference

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.

21 January 2018

1 reference

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.

21 January 2018

1 reference

Adjuvant Liraglutide and Insulin Versus Insulin Monotherapy in the Closed-Loop System in Type 1 Diabetes: A Randomized Open-Labeled Crossover Design Trial

21 January 2018

1 reference

Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.

21 January 2018

1 reference

Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes

21 January 2018

1 reference

The honeymoon phase: intersection of metabolism and immunology

21 January 2018

1 reference

Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program

21 January 2018

1 reference

Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study.

21 January 2018

1 reference

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

21 January 2018

1 reference

Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes

21 January 2018

1 reference

Measurement of gastric emptying in diabetes

21 January 2018

1 reference

What is the relative contribution of blood glucose levels at different time points of the day to HbA1c in Type 1 diabetes?

21 January 2018

1 reference

Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes

21 January 2018

1 reference

Relationships between gastric emptying, postprandial glycemia, and incretin hormones

21 January 2018

1 reference

Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial

21 January 2018

1 reference

Evidence of Extrapancreatic Glucagon Secretion in Man

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12911

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28211611%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference